FEATURED
FDA rejects Sydnexis’ NDA for low-dose atropine drop

SYD-101 still has the potential to become the first pharmaceutical option for progressive myopia for patients aged 3 to 14.

Earn FREE CE 24/7 with Courses by Eyes On Eyecare

Explore premium-quality, bite-sized courses featuring leading experts like Cecelia Koetting, OD, FAAO, and Cory Lappin, OD, MS, FAAO, and continuing education covering topics from ocular rosacea treatments to retinal disease.

TRENDING
Research